Biogen's dispute with Italy hits Tysabri
This article was originally published in Scrip
Executive Summary
A dispute with the Italian medicines agency AIFA has dragged on sales of the multiple sclerosis drug Tysabri (natalizumab) in the first half of this year, as revenues have had to be set aside pending the outcome of the argument. AIFA maintains that Biogen Idec, which is responsible for distribution of the product in Italy, has exceeded an agreed reimbursement limit, but the company counters that the agreement had expired.